Vor to Participate in Two Upcoming Investor Conferences
Vor Biopharma (Nasdaq: VOR) announced participation in two virtual investor conferences featuring key executives.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vor Biopharma (Nasdaq: VOR) announced participation in two virtual investor conferences featuring key executives. The Stifel 2021 Virtual Healthcare Conference will be held on November 15, 2021, at 4:00 PM ET, while the Evercore ISI 4th Annual HealthCONx Virtual Conference is scheduled for December 2, 2021, at 10:55 AM ET. Live webcasts for both events will be accessible via the company’s Investors section. Vor Biopharma focuses on engineering hematopoietic stem cells to improve treatments for blood cancers.
Details
News Market Reaction – VOR
The recorded move for VOR in the trading session of this news was +0.45%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell and genome engineering company, today announced that Robert Ang, M.B.B.S., MBA, Vor’s President and Chief Executive Officer, and Nathan Jorgensen, Ph.D., Vor’s Chief Financial Officer, will be participating in two upcoming virtual investor conferences:
Stifel 2021 Virtual Healthcare Conference
Fireside Chat Date: Monday, November 15, 2021
Time: 4:00 PM ET
Evercore ISI 4th Annual HealthCONx Virtual Conference
Fireside Chat Date: Thursday, December 2, 2021
Time: 10:55 AM ET
A live webcast of both fireside chats can be accessed via the Investors section of the Company's website at www.vorbio.com. An archived replay of each webcast will also be available.
About Vor Biopharma
Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contacts:
Investors:
Chris Brinzey
ICR Westwicke
+1 339-970-2843
chris.brinzey@westwicke.com
Media:
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.